NASDAQ Framework: Rhythm Pharmaceuticals Inc.
1: GlobeNewswire•yesterdayRhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity-- LB54640 has shown targeted effect on MC4R without hyperpigmentation -- BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have been dosed in the Company’s Phase 2 clinical trial evaluating LB54640, an investigational oral melanocortin-4 receptor (MC4R) agonist, in hypoGlobeNewswire•yesterdayRhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 6, 2024 to report its second quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register herGlobeNewswire•13 days agoRhythm Pharmaceuticals Announces New Employment Inducement GrantsBOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on July 8, 2024, the Compensation & Management Development Committee of Rhythm’s Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 19,200 shares of its common stock to six new employees. These iGlobeNewswire•16 days agoRhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific OfficerBOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al” Garfield, Ph.D. as Chief Scientific Officer, effective July 1. “We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring poteGlobeNewswire•26 days agoRhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorizatiGlobeNewswire•2 months agoRhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - - Separate analysis of patients across MC4R pathway diseases showed one year of treatment with setmelanotide improved NIH, WHO weight classifications - - Previously reported stage one results from Phase 2 DAYBREAK trial showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in Q3GlobeNewswire•2 months agoRhythm Pharmaceuticals Announces Participation at Upcoming Investor ConferenceBOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m. The fireside chat will be webcasted and avSimply Wall St.•2 months agoWhile Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this weekIt hasn't been the best quarter for Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) shareholders, since the share price...GlobeNewswire•2 months agoRhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl SyndromeIMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centresBOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the National Institute for Health and Care Excellence (NICE) has issued guidance that reInsider Monkey•3 months agoRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call TranscriptRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript May 7, 2024 Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-2.35058 EPS, expectations were $-2.12. Rhythm Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […] View Source2: Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. View Source3: About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA. View Source
Rhythm Pharmaceuticals, Inc., headquartered in Boston, Massachusetts, is a commercial-stage biopharmaceutical company dedicated to transforming the lives of patients and their families living with rare neuroendocrine diseases. The company's lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved by the FDA for chronic weight management in patients with specific genetic forms of obesity, and has also received authorization from the European Commission and the UK's MHRA for similar indications. Rhythm is advancing a broad clinical development program for setmelanotide and other investigational MC4R agonists, including LB54640 and RM-718, targeting various rare diseases 4567.
4: GlobeNewswire•yesterdayRhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity-- LB54640 has shown targeted effect on MC4R without hyperpigmentation -- BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have been dosed in the Company’s Phase 2 clinical trial evaluating LB54640, an investigational oral melanocortin-4 receptor (MC4R) agonist, in hypoGlobeNewswire•yesterdayRhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 6, 2024 to report its second quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register herGlobeNewswire•13 days agoRhythm Pharmaceuticals Announces New Employment Inducement GrantsBOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on July 8, 2024, the Compensation & Management Development Committee of Rhythm’s Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 19,200 shares of its common stock to six new employees. These iGlobeNewswire•16 days agoRhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific OfficerBOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al” Garfield, Ph.D. as Chief Scientific Officer, effective July 1. “We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring poteGlobeNewswire•26 days agoRhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorizatiGlobeNewswire•2 months agoRhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - - Separate analysis of patients across MC4R pathway diseases showed one year of treatment with setmelanotide improved NIH, WHO weight classifications - - Previously reported stage one results from Phase 2 DAYBREAK trial showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in Q3GlobeNewswire•2 months agoRhythm Pharmaceuticals Announces Participation at Upcoming Investor ConferenceBOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m. The fireside chat will be webcasted and avSimply Wall St.•2 months agoWhile Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this weekIt hasn't been the best quarter for Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) shareholders, since the share price...GlobeNewswire•2 months agoRhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl SyndromeIMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centresBOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the National Institute for Health and Care Excellence (NICE) has issued guidance that reInsider Monkey•3 months agoRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call TranscriptRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript May 7, 2024 Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-2.35058 EPS, expectations were $-2.12. Rhythm Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […] View Source5: Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. View Source6: About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists LB54640 and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA. View Source7: Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or... View Source
NO
Rhythm Pharmaceuticals, Inc. is not currently led by its founders, nor is there evidence suggesting that the founders are heavily involved. The company was founded by Bart Henderson in February 2010, but recent leadership appointments, such as Alastair Garfield, Ph.D., as Chief Scientific Officer, indicate that the current leadership team is composed of individuals who were not part of the founding team 89.
Rhythm Pharmaceuticals, Inc. is not currently led by its founders, nor is there evidence suggesting that the founders are heavily involved. The company was founded by Bart Henderson in February 2010, but recent leadership appointments, such as Alastair Garfield, Ph.D., as Chief Scientific Officer, indicate that the current leadership team is composed of individuals who were not part of the founding team 89.
8: Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer View Source9: Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA. View Source
MEDIUM RISK
Rhythm Pharmaceuticals, Inc. shows a mixed financial situation. The company has reported significant revenue growth, with a 173.52% increase over the last twelve months as of Q1 2024 and a quarterly revenue growth of 126.41% for Q1 2024 10. Additionally, the company has a high gross profit margin of 88.37%, indicating efficient cost management 11. However, the company has also experienced increasing losses, as highlighted by a recent downgrade from BofA Securities due to slower-than-anticipated sales of IMCIVREE 12. Furthermore, the company's stock is in overbought territory, and there is an expectation that net income may drop this year 13. These factors suggest that while the company has strong revenue growth and profit margins, the financial outlook is uncertain, warranting a medium risk assessment.
Rhythm Pharmaceuticals, Inc. shows a mixed financial situation. The company has reported significant revenue growth, with a 173.52% increase over the last twelve months as of Q1 2024 and a quarterly revenue growth of 126.41% for Q1 2024 10. Additionally, the company has a high gross profit margin of 88.37%, indicating efficient cost management 11. However, the company has also experienced increasing losses, as highlighted by a recent downgrade from BofA Securities due to slower-than-anticipated sales of IMCIVREE 12. Furthermore, the company's stock is in overbought territory, and there is an expectation that net income may drop this year 13. These factors suggest that while the company has strong revenue growth and profit margins, the financial outlook is uncertain, warranting a medium risk assessment.
10: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has experienced a notable surge in its stock price, with an impressive 225.8% one-year total return as of the latest data. The company's recent performance is underpinned by significant revenue growth, with the last twelve months as of Q1 2024 showing a robust 173.52% increase. This uptrend is further exemplified by a quarterly revenue growth of 126.41% for Q1 2024, highlighting the company's strong sales momentum. View Source11: Investors considering Rhythm Pharmaceuticals should be aware of the company's market cap, which stands at $3.26 billion, reflecting investor valuation of the company's potential. Additionally, the company's gross profit margin is remarkably high at 88.37%, indicative of its efficiency in managing the costs associated with its goods sold and reinforcing the InvestingPro Tip highlighting the company's impressive gross profit margins. View Source12: Meanwhile, the European Medicines Agency's Committee for Medicinal Products for Human Use endorsed Rhythm's obesity drug, IMCIVREE, for use in children aged 2 to 6 years with certain rare genetic disorders. This positive opinion is currently under review by the European Commission. However, BofA Securities recently downgraded Rhythm Pharmaceuticals from 'Buy' to 'Neutral' due to slower-than-anticipated sales of IMCIVREE, particularly for Bardet-Biedl Syndrome. View Source13: While the company's stock is currently trading near its 52-week high, with a price percentage of 99.96% of that peak, the InvestingPro Tips suggest caution due to the stock being in overbought territory according to the RSI, and the expectation that net income may drop this year. For investors seeking a deeper dive into Rhythm Pharmaceuticals' financials and future prospects, there are additional InvestingPro Tips available at InvestingPro. Use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, and gain access to a total of 19 InvestingPro Tips that could further inform investment decisions. View Source
14: GlobeNewswire•yesterdayRhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity-- LB54640 has shown targeted effect on MC4R without hyperpigmentation -- BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have been dosed in the Company’s Phase 2 clinical trial evaluating LB54640, an investigational oral melanocortin-4 receptor (MC4R) agonist, in hypoGlobeNewswire•yesterdayRhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 6, 2024 to report its second quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register herGlobeNewswire•13 days agoRhythm Pharmaceuticals Announces New Employment Inducement GrantsBOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on July 8, 2024, the Compensation & Management Development Committee of Rhythm’s Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 19,200 shares of its common stock to six new employees. These iGlobeNewswire•16 days agoRhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific OfficerBOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al” Garfield, Ph.D. as Chief Scientific Officer, effective July 1. “We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring poteGlobeNewswire•26 days agoRhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorizatiGlobeNewswire•2 months agoRhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - - Separate analysis of patients across MC4R pathway diseases showed one year of treatment with setmelanotide improved NIH, WHO weight classifications - - Previously reported stage one results from Phase 2 DAYBREAK trial showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in Q3GlobeNewswire•2 months agoRhythm Pharmaceuticals Announces Participation at Upcoming Investor ConferenceBOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m. The fireside chat will be webcasted and avSimply Wall St.•2 months agoWhile Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this weekIt hasn't been the best quarter for Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) shareholders, since the share price...GlobeNewswire•2 months agoRhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl SyndromeIMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centresBOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the National Institute for Health and Care Excellence (NICE) has issued guidance that reInsider Monkey•3 months agoRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call TranscriptRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript May 7, 2024 Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-2.35058 EPS, expectations were $-2.12. Rhythm Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […] View Source15: BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have been dosed in the Company’s Phase 2 clinical trial evaluating LB54640, an investigational oral melanocortin-4 receptor (MC4R) agonist, in hypothalamic obesity. View Source
Rhythm Pharmaceuticals, Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its portfolio of MC4R agonists to address various rare neuroendocrine diseases. The company is actively progressing its lead product, IMCIVREE® (setmelanotide), through additional clinical trials to expand its indications, including a pivotal Phase 3 study and a positive CHMP opinion for use in younger patients with Bardet-Biedl Syndrome or POMC, PCSK1, or LEPR deficiencies [fERROR]Rhythm Pharmaceuticals, Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its portfolio of MC4R agonists to address various rare neuroendocrine diseases. The company is actively progressing its lead product, IMCIVREE® (setmelanotide), through additional clinical trials to expand its indications, including a pivotal Phase 3 study and a positive CHMP opinion for use in younger patients with Bardet-Biedl Syndrome or POMC, PCSK1, or LEPR deficiencies [fERROR][fERROR]Rhythm Pharmaceuticals, Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its portfolio of MC4R agonists to address various rare neuroendocrine diseases. The company is actively progressing its lead product, IMCIVREE® (setmelanotide), through additional clinical trials to expand its indications, including a pivotal Phase 3 study and a positive CHMP opinion for use in younger patients with Bardet-Biedl Syndrome or POMC, PCSK1, or LEPR deficiencies [fERROR][fERROR][fERROR]Rhythm Pharmaceuticals, Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its portfolio of MC4R agonists to address various rare neuroendocrine diseases. The company is actively progressing its lead product, IMCIVREE® (setmelanotide), through additional clinical trials to expand its indications, including a pivotal Phase 3 study and a positive CHMP opinion for use in younger patients with Bardet-Biedl Syndrome or POMC, PCSK1, or LEPR deficiencies [fERROR][fERROR][fERROR]. Additionally, Rhythm has initiated a Phase 2 trial for LB54640, an investigational oral MC4R agonist, targeting hypothalamic obesity, and is developing RM-718 along with a suite of preclinical small molecules for congenital hyperinsulinism [fERROR]Rhythm Pharmaceuticals, Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its portfolio of MC4R agonists to address various rare neuroendocrine diseases. The company is actively progressing its lead product, IMCIVREE® (setmelanotide), through additional clinical trials to expand its indications, including a pivotal Phase 3 study and a positive CHMP opinion for use in younger patients with Bardet-Biedl Syndrome or POMC, PCSK1, or LEPR deficiencies [fERROR][fERROR][fERROR]. Additionally, Rhythm has initiated a Phase 2 trial for LB54640, an investigational oral MC4R agonist, targeting hypothalamic obesity, and is developing RM-718 along with a suite of preclinical small molecules for congenital hyperinsulinism [fERROR][fERROR]Rhythm Pharmaceuticals, Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its portfolio of MC4R agonists to address various rare neuroendocrine diseases. The company is actively progressing its lead product, IMCIVREE® (setmelanotide), through additional clinical trials to expand its indications, including a pivotal Phase 3 study and a positive CHMP opinion for use in younger patients with Bardet-Biedl Syndrome or POMC, PCSK1, or LEPR deficiencies [fERROR][fERROR][fERROR]. Additionally, Rhythm has initiated a Phase 2 trial for LB54640, an investigational oral MC4R agonist, targeting hypothalamic obesity, and is developing RM-718 along with a suite of preclinical small molecules for congenital hyperinsulinism [fERROR][fERROR]. The company also aims to enhance its market presence through strategic licensing agreements and new employment inducement grants to support its expanding operations [fERROR]Rhythm Pharmaceuticals, Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its portfolio of MC4R agonists to address various rare neuroendocrine diseases. The company is actively progressing its lead product, IMCIVREE® (setmelanotide), through additional clinical trials to expand its indications, including a pivotal Phase 3 study and a positive CHMP opinion for use in younger patients with Bardet-Biedl Syndrome or POMC, PCSK1, or LEPR deficiencies [fERROR][fERROR][fERROR]. Additionally, Rhythm has initiated a Phase 2 trial for LB54640, an investigational oral MC4R agonist, targeting hypothalamic obesity, and is developing RM-718 along with a suite of preclinical small molecules for congenital hyperinsulinism [fERROR][fERROR]. The company also aims to enhance its market presence through strategic licensing agreements and new employment inducement grants to support its expanding operations [fERROR][fERROR]Rhythm Pharmaceuticals, Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its portfolio of MC4R agonists to address various rare neuroendocrine diseases. The company is actively progressing its lead product, IMCIVREE® (setmelanotide), through additional clinical trials to expand its indications, including a pivotal Phase 3 study and a positive CHMP opinion for use in younger patients with Bardet-Biedl Syndrome or POMC, PCSK1, or LEPR deficiencies [fERROR][fERROR][fERROR]. Additionally, Rhythm has initiated a Phase 2 trial for LB54640, an investigational oral MC4R agonist, targeting hypothalamic obesity, and is developing RM-718 along with a suite of preclinical small molecules for congenital hyperinsulinism [fERROR][fERROR]. The company also aims to enhance its market presence through strategic licensing agreements and new employment inducement grants to support its expanding operations [fERROR][fERROR][fERROR]Rhythm Pharmaceuticals, Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its portfolio of MC4R agonists to address various rare neuroendocrine diseases. The company is actively progressing its lead product, IMCIVREE® (setmelanotide), through additional clinical trials to expand its indications, including a pivotal Phase 3 study and a positive CHMP opinion for use in younger patients with Bardet-Biedl Syndrome or POMC, PCSK1, or LEPR deficiencies [fERROR][fERROR][fERROR]. Additionally, Rhythm has initiated a Phase 2 trial for LB54640, an investigational oral MC4R agonist, targeting hypothalamic obesity, and is developing RM-718 along with a suite of preclinical small molecules for congenital hyperinsulinism [fERROR][fERROR]. The company also aims to enhance its market presence through strategic licensing agreements and new employment inducement grants to support its expanding operations [fERROR][fERROR][fERROR][fERROR]Rhythm Pharmaceuticals, Inc. has outlined an ambitious product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its portfolio of MC4R agonists to address various rare neuroendocrine diseases. The company is actively progressing its lead product, IMCIVREE® (setmelanotide), through additional clinical trials to expand its indications, including a pivotal Phase 3 study and a positive CHMP opinion for use in younger patients with Bardet-Biedl Syndrome or POMC, PCSK1, or LEPR deficiencies [fERROR][fERROR][fERROR]. Additionally, Rhythm has initiated a Phase 2 trial for LB54640, an investigational oral MC4R agonist, targeting hypothalamic obesity, and is developing RM-718 along with a suite of preclinical small molecules for congenital hyperinsulinism [fERROR][fERROR]. The company also aims to enhance its market presence through strategic licensing agreements and new employment inducement grants to support its expanding operations [fERROR][fERROR][fERROR][fERROR].